Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections
Launched by RIGSHOSPITALET, DENMARK · Mar 23, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how patients feel about receiving injections of a medication called dexamethasone in both eyes on the same day. Dexamethasone is often used to treat conditions like diabetic macular edema and macular edema from retinal vein occlusion. Many patients face the challenge of frequent visits to the doctor for treatment, especially if both eyes are affected. The trial aims to understand patient preferences regarding same-day injections and to identify any factors that might influence their choices, such as personal experiences or financial considerations.
To participate in this study, individuals must be over 18 years old, have received at least one dexamethasone injection in either eye, and be able to understand and respond to questions in Danish. Participants will be asked about their thoughts and feelings regarding the treatment process, helping researchers find ways to make the experience better for patients. This could lead to improvements in how this treatment is delivered, making it more convenient and efficient for everyone involved.
Gender
ALL
Eligibility criteria
- • Inclusion criteria
- • Having received at least one intravitreal dexamethasone implant in either eye
- • \>18 years of age
- • Capacity to comprehend and answer questions in Danish language
- • Signed informed consent
- • Exclusion criteria
- • • No intravitreal dexamethasone implant received within the last 12 months
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Glostrup, , Denmark
Patients applied
Trial Officials
Miklos Schneider, MD, PhD
Principal Investigator
Rigshospitalet, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported